FDA Approves New Alzheimer’s PET Imaging Agent From Lantheus

FDA approves new Alzheimer’s PET imaging agent from Lantheus

Tauklarify, also known as MK-6240, is a radiodiagnostic agent indicated for positron emission tomography scans of adults suspected of having the degenerative brain disease.

FDA Approves Brain-Imaging Agent for Alzheimer's

US FDA approves Lantheus' brain-imaging agent for Alzheimer's assessment

FDA Approves Tauklarify as New Tau Imaging Agent for Alzheimer’s Evaluation

WASHINGTON D.C (VINnews) — The U.S. Food and Drug Administration on Thursday approved Tauklarify, a brain PET imaging agent designed to help evaluate adults with cognitive impairment for Alzheimer’s disease. Tauklarify, known chemically as florquinitau F 18 injection and previously studied as MK-6240, detects tau neurofibrillary tangle pathology in the brain. The information it provides […]

Lantheus Announces FDA Approval of TAUKLARIFY™ (Florquinitau F 18 Injection), an F18-Labeled Tau PET Imaging Agent for Alzheimer’s Disease

BEDFORD, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ('Lantheus” or the 'Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced U.S. Food and Drug Administration (FDA) approval of TAUKLARIFY™ (florquinitau F 18 injection), also referred to as MK-6240, a radiodiagnostic agent indicated for …

Enigma Biomedical USA Announces FDA Approval of TAUKLARIFY™ (florquinitau F 18 injection) for Use in Patients Being Evaluated for Alzheimer’s Disease

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Aug 14, 2026-